Eurostarsprojekt, REDCATH , 9255, Bactiguard AB

Important results from the project

The purpose and aim of the project was to develop a new generation of central venous catheters (changed early in the project to hemodialysis catheters, HDC) that prevents / delays the development of catheter-related infections and prevents thrombosis. The purpose and goal have been met and there is now a validated prototype of a HDC with a surface consisting of heparin in combination with a biocompatible noble metal coating which prevents both infection and thrombosis. The prototype is ready for a CE marking process.

Expected long term effects

A new combination coating with anti-thrombogenic and anti-infective properties has been developed and successfully tested on a hemodialysis catheter (HDC). The new HDC will be CE marked either by Bactiguard or by a potential licensing partner. There is also an ambition to find license partners in other applications within vascular access, such as vascular grafts. The market for medical devices that prevent healthcare related problems such as infections and thromboses is growing rapidly and there is great potential for the new generation of HDCs that has been developed in the project.

Approach and implementation

Through the project Bactiguard AB and Biointeractions Ltd have been able to combine their state-of-the-art technologies in infection control and blood compatibility. The anti-thrombogenic and anti-infective properties have been demonstrated with good results in relevant in vitro tests and a HDC with the combination coating has also passed relevant performance and biocompatibility testing.